Bad prognostic factors for DFS and OS from CR in the 164 patient randomized for postremission therapy
| . | Univariate . | Multivariate . | |
|---|---|---|---|
| P value* . | P value* . | HR (95% CI)† . | |
| For DFS | |||
| Advanced age | .01 | .04 | 1.33 (1.01-1.74) |
| AML type | .02 | .05 | 1.75 (1.01-3.02) |
| High-risk karyotype | < .001 | < .001 | 8.40 (3.27-21.6) |
| Intensive consolidation | .04 | .05 | 1.51 (1.00-2.27) |
| For OS from CR | |||
| Advanced age | .045 | NS | 1.16 (0.85-1.59) |
| AML type | .11 | NS | 0.94 (0.52-1.71) |
| High-risk karyotype | < .001 | NS | 1.81 (0.75-4.39) |
| Intensive consolidation | .03 | .04 | 1.59 (1.02-2.47) |
| . | Univariate . | Multivariate . | |
|---|---|---|---|
| P value* . | P value* . | HR (95% CI)† . | |
| For DFS | |||
| Advanced age | .01 | .04 | 1.33 (1.01-1.74) |
| AML type | .02 | .05 | 1.75 (1.01-3.02) |
| High-risk karyotype | < .001 | < .001 | 8.40 (3.27-21.6) |
| Intensive consolidation | .04 | .05 | 1.51 (1.00-2.27) |
| For OS from CR | |||
| Advanced age | .045 | NS | 1.16 (0.85-1.59) |
| AML type | .11 | NS | 0.94 (0.52-1.71) |
| High-risk karyotype | < .001 | NS | 1.81 (0.75-4.39) |
| Intensive consolidation | .03 | .04 | 1.59 (1.02-2.47) |
NS indicates not significant.
P values are given for age as a continuous variable, AML type (de novo vs post-MDS), and karyotype as a 2-class variable (standard-risk, high-risk).
HRs are given for the high-risk as compared with the standard-risk karyotype subset, for 5-year age increment, for post-MDS as compared with de novo AML, and for intensive as compared with ambulatory post-remission therapy.